SavedAdd your journal

Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

Recent Reports in Age Related Macular Degeneration

Yaşa Bağlı Makula Dejeneresansında Son Çalışmalar

Nurten ÜNLÜ
Pages
69–74
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review clinical re- search for the anti-VEGF agents used in routine clinical practice, data from real life utilization and data from switching therapies are summarized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There are many reports on the treatment patterns for neovascu- lar age related macular degeneration.
📊
Key Findings & Data:There are many reports on the treatment patterns for neovascu- lar age related macular degeneration.
💡
Conclusion & Impact:In this review clinical re- search for the anti-VEGF agents used in routine clinical practice, data from real life utilization and data from switching therapies are summarized.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

There are many reports on the treatment patterns for neovascu- lar age related macular degeneration. In this review clinical re- search for the anti-VEGF agents used in routine clinical practice, data from real life utilization and data from switching therapies are summarized.

Özet

Yaş tip yaşa bağlı makula dejenerasyonunun tedavisi ile ilgili çok sayıda çalışma mevcuttur. Bu derlemede günümüzde kullanıl- makta olan anti VEGF ajanlar ile ilgili klinik araştırmalar, ger- çek yaşam çalışmaları ve tedavi değişikliğinin değerlendirildiği araştırmalar özetlenmiştir.

🔖

Cite This Article

ÜNLÜ, N. (2017). Recent Reports in Age Related Macular Degeneration. Retina-Vitreus, Cilt: 26 - Sayı: 0, 69–74. https://ajindex.com/articles/304922

References (9)

  1. Maguire MG, Martin DF, Ying G, et al Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovas- cular Age-Related Macular Degeneration The Comparison of Age-Related Macular Degeneration Treatments Trials, Ophthal- mology 2016; 123: 1751-61
  2. Lee JE, Shin JP, Kim HW, et al. Eff icacy of fixed-dosing afiber- cept for treating polypoidal choroidal vasculopathy: 1-year re- sults of the VAULT study. Graefes Arch Clin Exp Ophthalmol 2016 Sep 14. [Epub ahead of print] Visual Outcome in Patients with Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. (EVEREST II) (Clini- calTrials.gov identifier: NCT01846273) AAO 2016
  3. Wykoff CC, Brown DM, Ou W, Payne JF, Clark LC. TREX:Month- ly vs Treat and Extend for Neovascular AMD AAO 2016 Subspe- ciality Day Section IX:Late breaking Develepment Part I P. 71-2.
  4. Barthelmes D, Nguyen V, Arnold J, et al. Twelve-Month Outco- mes of “Treat and Extend” afl ibercept Therapy for Neovascular Age-Related Macular Degeneration ARVO 2016; Poster Board Number: A0158 Waldstein SM, Simader C, Staurenghi G, et al. Morphology and visual acuity in afl ibercept and ranibizumab therapy for neovas- cular age related mavular degeneration in the VIEW trials. Op- hthamology 2016; 123: 1521-9.
  5. Sarraf D, London NJ, Khurana RN, et al. Ranibizumab treat- ment for pigment epithelial detachment secondary to neovas- cular age-related macular detachment Post Hoc analysis of the HARBOR Study Ophthalmology. 2016; 123:2213-24
  6. Holz FG, Tadayoni R, beatty S, et al. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with an- ti-VEGF agents: an instrumental variable analysis of the AURA study. Eye 2016; 30: 1063–71
  7. Hykin P, Chakravarthy U, Lotery A, et al. A retrospective study of the real life utilization and eff ectiveness of ranibizumab the- rapy for neovascular age related macular degeneration in the UK Clin. Ophthalmol 2016; 10: 87-96.
  8. Kim LN, Menta H, Barthelmes D, Nguyen V, Gillies MC. Me- ta-analysis of real-world outcomes of intravıtreal ranıbızumab for the treatment of neovascular age-related macular degenera- tıon. Retina 2016; 36: 1418-31.
  9. Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F. Treatment Frequency and Dosing Interval of Ranibizumab and Afl ibercept for Neovascular Age-Related Macular Degenera- tion in Routine Clinical Practice in the USA. PLoS One. 2015; 10(7):e0133968. Gillies MC, Nguyen V, Daien V, Arnold JJ, Morl